Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP30663 first-in-human single ascending dose study in healthy male volunteers
NL-OMON46496Phase 1Active, not recruiting
- Sponsor
- Acesion Pharma
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AP30663 in Atrial fibrillation (AFib) and supraventricular tachycardia (SVT), sponsored by Acesion Pharma. Started Jan 2018; status: active, not recruiting.
02
Drugs
AP30663
03
Conditions
Atrial fibrillation (AFib)supraventricular tachycardia (SVT)
Beyond the preview
Go deeper on NL-OMON46496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46496.